Inflammatory diseases articles from across Nature Portfolio

In this study, we use a transcriptomic approach as a starting point to explore the heterogeneity of human GATA3-expressing lymphocytes across different tissues and disease contexts. We identify, characterize and functionally validate an abundant progenitor-like memory T cell population with the potential to sustain pathogenic T_H2 cell inflammation.

Ratley, Zeldin et al. implicate xylene in the pathogenesis of atopic dermatitis by combining spatial analysis and patient surveys with prior epidemiological and mechanistic data. They propose that exposure of healthy skin commensals to xylene, benzene and isocyantes in synthetic fabrics disrupts normal lipid metabolism and activates itching.

In this Resource, the authors integrate multiomics data to show the effect of the transcription factors Blimp-1 and c-Maf on IL-10 and type 1 and 17 responses, which together protect against pathobiont-induced colitis.

Here, the authors describe biallelic loss-of-function variants in human SHARPIN in individuals with autoinflammation and immunodeficiency, termed sharpenia. They also successfully treat one of these individuals with TNF inhibitors.

Glucocorticoids reprogram the mitochondrial metabolism of macrophages, resulting in increased and sustained production of the anti-inflammatory metabolite itaconate and, as a consequence, inhibition of the inflammatory response.

Short-chain fatty acids (SCFAs) are microbial metabolites that regulate mucosal barrier integrity and immune cell functions. This Review summarizes latest insights into how SCFA levels might determine inflammatory and allergic disease outcomes by controlling the crosstalk between diet, the microbiome and immunity.

In this study, we use a transcriptomic approach as a starting point to explore the heterogeneity of human GATA3-expressing lymphocytes across different tissues and disease contexts. We identify, characterize and functionally validate an abundant progenitor-like memory T cell population with the potential to sustain pathogenic T_H2 cell inflammation.

Although anti-inflammatory drugs have shown promising results in preclinical cardiovascular research, they have yielded little benefit in clinical trials. Before we can expect positive outcomes, we need to find ways of stratifying patients based on their infectious, inflammatory and autoimmune profile, and identify the right time of treatment.

The development of therapies for ischemic stroke requires a deep understanding of the immune response to injury. Analysis now defines immune cell origin, disease stage-specific responses, and the effects of age and sex after ischemic stroke.